Login to Your Account

Genentech, Xoma's Raptiva Receives Psoriasis Approval

By Kim Coghill

Wednesday, October 29, 2003
Genentech Inc. and partner XOMA Ltd. won FDA approval for Raptiva, a biologic for psoriasis that can be self-administered once weekly on a continuous basis. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription